Color, Scent and Size: Exploring Women's Preferences Around Design Characteristics of Drug-Releasing Vaginal Rings

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2022 Mar 16

PMID 35294694

Authors

Xinyu Zhao

Cecilia Milford

Jenni Smit

Bongiwe Zulu

Peter Boyd

R Karl Malcolm

Mags Beksinska

Affiliations

Soon will be listed here.

Abstract

Steroid-releasing vaginal rings are available for contraception and estrogen replacement therapy, and a new antiretroviral-releasing ring was recently approved for HIV prevention. Marketed rings are white or transparent in appearance, non-scented, and supplied as one-size-fits-all devices with diameters ranging from 54 to 56 mm. In this study, drug-free silicone elastomer rings were manufactured in different sizes, colors and scents, and the opinions/preferences of 16 women (eThekwini District, South Africa; 20-34 years) assessed through focus group discussions and thematic analysis. Opinions varied on ring color and scent, with some women preferring specific colors or scent intensities, while for others these attributes were unimportant. Concerns about color and scent were linked to perceptions around vaginal health and safety related to chemical composition. There was greater agreement on preferred ring size; flexibility and width were considered important factors for insertion and comfort. Greater choice with ring products could facilitate acceptability and overall uptake.

Citing Articles

HIV Prevention Product Acceptability and Preference Among Women in Sub-Saharan Africa to Inform Novel Biomedical Options in Development: A Systematic Review.

Makoni W, Lorenzetti L, Mancuso N, Luecke E, Dinh N, Deshpande A AIDS Behav. 2024; 29(1):257-293.

PMID: 39422786 DOI: 10.1007/s10461-024-04529-2.

High adherence to intermittent and continuous use of a contraceptive vaginal ring among women in a randomized controlled trial in Kigali, Rwanda.

Kestelyn E, Van Nuil J, Umulisa M, Umutoni G, Uwingabire A, De Baetselier I Front Glob Womens Health. 2024; 5:1278981.

PMID: 38680542 PMC: 11047128. DOI: 10.3389/fgwh.2024.1278981.

References

Ramarao S, Obare F, Ishaku S, Mane B, Clark H, Liambila W . Do Women Find the Progesterone Vaginal Ring Acceptable? Findings from Kenya, Nigeria, and Senegal. Stud Fam Plann. 2018; 49(1):71-86. DOI: 10.1111/sifp.12046. View

Boyd P, Merkatz R, Variano B, Malcolm R . The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals. Expert Opin Drug Deliv. 2020; 17(11):1519-1540. DOI: 10.1080/17425247.2020.1798927. View

Bakke A, Zaveri T, Higgins M, Ziegler G, Hayes J . Design aspects of vaginal applicators that influence acceptance among target users. Sci Rep. 2021; 11(1):9802. PMC: 8105386. DOI: 10.1038/s41598-021-89284-3. View

Jain A, Obare F, Ramarao S, Askew I . Reducing unmet need by supporting women with met need. Int Perspect Sex Reprod Health. 2013; 39(3):133-41. DOI: 10.1363/3913313. View

Griffin J, Ridgeway K, Montgomery E, Torjesen K, Clark R, Peterson J . Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis. PLoS One. 2019; 14(11):e0224898. PMC: 6839883. DOI: 10.1371/journal.pone.0224898. View

Barnhart K, Izquierdo A, Pretorius E, Shera D, Shabbout M, Shaunik A . Baseline dimensions of the human vagina. Hum Reprod. 2006; 21(6):1618-22. DOI: 10.1093/humrep/del022. View

Minnis A, Roberts S, Agot K, Weinrib R, Ahmed K, Manenzhe K . Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa. AIDS Behav. 2018; 22(8):2662-2673. PMC: 6097726. DOI: 10.1007/s10461-018-2078-5. View

Stegemann S, Riedl R, Sourij H . Identification of different shapes, colors and sizes of standard oral dosage forms in diabetes type 2 patients-A pilot study. Int J Pharm. 2016; 517(1-2):112-118. DOI: 10.1016/j.ijpharm.2016.11.066. View

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

10.

Murphy D, McCoy C, Plagianos M, Ramarao S, Merkatz R, Clark H . Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring. Contraception. 2019; 100(3):241-246. DOI: 10.1016/j.contraception.2019.06.013. View

11.

Roumen F, Dieben T . Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception. 1999; 59(1):59-62. DOI: 10.1016/s0010-7824(98)00145-0. View

12.

Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T . Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Cult Health Sex. 2019; 21(11):1209-1224. PMC: 6639142. DOI: 10.1080/13691058.2018.1552989. View

13.

Duby Z, Katz A, Browne E, Mutero P, Etima J, Zimba C . Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2019; 24(2):617-628. PMC: 6815681. DOI: 10.1007/s10461-019-02514-8. View

14.

Montgomery E, Beksinska M, Mgodi N, Schwartz J, Weinrib R, Browne E . End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J Int AIDS Soc. 2019; 22(5):e25283. PMC: 6506690. DOI: 10.1002/jia2.25283. View

15.

Rantell A . Vaginal Pessaries for Pelvic Organ Prolapse and Their Impact on Sexual Function. Sex Med Rev. 2019; 7(4):597-603. DOI: 10.1016/j.sxmr.2019.06.002. View

16.

Jenkins A, Money D, ODoherty K . Is the vaginal cleansing product industry causing harm to women?. Expert Rev Anti Infect Ther. 2020; 19(3):267-269. DOI: 10.1080/14787210.2020.1822166. View

17.

Ashmore J, Henwood R . Choice or no choice? The need for better branded public sector condoms in South Africa. South Afr J HIV Med. 2018; 16(1):353. PMC: 5843224. DOI: 10.4102/sajhivmed.v16i1.353. View

18.

de Craen A, Roos P, de Vries A, Kleijnen J . Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ. 1996; 313(7072):1624-6. PMC: 2359128. DOI: 10.1136/bmj.313.7072.1624. View

19.

Baeten J, Palanee-Phillips T, Brown E, Schwartz K, Soto-Torres L, Govender V . Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375(22):2121-2132. PMC: 4993693. DOI: 10.1056/NEJMoa1506110. View

20.

NASH H, Brache V, Jackanicz T, Harmon T . Estradiol delivery by vaginal rings: potential for hormone replacement therapy. Maturitas. 1997; 26(1):27-33. DOI: 10.1016/s0378-5122(96)01072-9. View